Summary

While cardiac troponin is essential in the diagnosis of acute myocardial infarction, it is possible that other biomarkers may improve diagnosis in patients who present early or may have other causes of troponin elevation. This article presents results of the COPeptin in ED [COPED] study indicating that copeptin may be a useful biomarker to rule out NSTEMI among patients who present to the emergency department with acute chest pain but have a pacemaker and a normal troponin value at baseline.